Johnson & Johnson, one of the few remaining companies with a top credit rating, is no longer at risk of a downgrade, S&P ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

A product that was assumed to be benign turns out to be dangerous. A heavily marketed new drug has serious side effects. A medical device leaves a trail of complications. In all of these scenarios ...

Johnson & Johnson's annual revenue as of Dec. 31 stood at $88.82 billion. According to the company’s Q1 2025 earnings release on April 15, it posted revenues of $21.89 billion and EPS of $2.77 ...

Johnson & Johnson JNJ engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. Don't Miss: Deloitte's fastest-growing software company ...